KR890014107A - 백금 화학 요법약제 - Google Patents

백금 화학 요법약제 Download PDF

Info

Publication number
KR890014107A
KR890014107A KR1019890003136A KR890003136A KR890014107A KR 890014107 A KR890014107 A KR 890014107A KR 1019890003136 A KR1019890003136 A KR 1019890003136A KR 890003136 A KR890003136 A KR 890003136A KR 890014107 A KR890014107 A KR 890014107A
Authority
KR
South Korea
Prior art keywords
platinum compound
composition
platinum
cyclobutanedicarboxylate
loperamide
Prior art date
Application number
KR1019890003136A
Other languages
English (en)
Inventor
레지널드 헤럽 케니스
Original Assignee
아이.씨.위샤트
존슨 맛쎄이 퍼블릭 리미티드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아이.씨.위샤트, 존슨 맛쎄이 퍼블릭 리미티드 캄파니 filed Critical 아이.씨.위샤트
Publication of KR890014107A publication Critical patent/KR890014107A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

내용 없음.

Description

백금 화학 요법약제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 암을 치료하는 데 있어서 동시, 분리 혹은 연속적인 사용을 위한 결합된 제제로서 다음의 일반식(I)
    (상기 식에서 R은 수소, 메틸, 에틸 혹은 3~9개의 탄소원자를 가진 직쇄 혹은 분기쇄 혹은 고리형 알킬기이고, A는 염소원자 혹은 수산기이고 백금 원자가 Pt(IV) 상태로 있을 때 존재하고, 각각의 B는 염소원자이거나 함께 말로네이트 혹은 치환된 말로네이트를 형성하며, R이 수소이면 B가 염소가 아님)의 백금 배위 화합물과 로퍼아미드로 이루어지는 것을 특징으로하는 화학 요법 약제.
  2. 제1항에 있어서, 백금 화합물과 로퍼아미드가 각각 경구단위 투여량 형태로 있는 것을 특징으로 하는 약제.
  3. 제1항에 혹은 제2항에 있어서, 백금 화합물이 함께 1,1-시클로 부탄디카르복실레이트를 형성하는 B 치환기를 가지는 것을 특징으로 하는 약제.
  4. 제3항에 있어서, 백금 화합물이 카르보플랜틴 인 것을 특징으로 하는 약제.
  5. 제약적으로 수용할수 있는 담체 혹은 희석제와 함께 식I의 백금 화합물과 로퍼아미드로 이루어지는 것을 특징으로 하는 제약적 조성물.
  6. 제5항에 있어서, 경구 단위 투여량 형태인 것을 특징으로 하는 조성물.
  7. 제5항 또는 제6항에 있어서, 백금화합물이 함게 1,1-시클로 부탄디카르복실레이트를 형성하는 B치환기를 가지는 것을 특징으로 하는 조성물.
  8. 제7항에 있어서, 백금 화합물이 카르보플래틴 인 것을 특징으로 하는 조성물.
    ※ 참고사항:최초출원 내용에 의하여 공개하는 것임.
KR1019890003136A 1988-03-16 1989-03-14 백금 화학 요법약제 KR890014107A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB888806224A GB8806224D0 (en) 1988-03-16 1988-03-16 Platinum chemotherapeutic product
GBP8806224 1988-03-16

Publications (1)

Publication Number Publication Date
KR890014107A true KR890014107A (ko) 1989-10-21

Family

ID=10633521

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890003136A KR890014107A (ko) 1988-03-16 1989-03-14 백금 화학 요법약제

Country Status (13)

Country Link
US (1) US4892735A (ko)
EP (1) EP0339772A1 (ko)
JP (1) JPH0296523A (ko)
KR (1) KR890014107A (ko)
AU (1) AU613720B2 (ko)
DK (1) DK105889A (ko)
FI (1) FI890951A (ko)
GB (1) GB8806224D0 (ko)
IL (1) IL89502A0 (ko)
NO (1) NO891122L (ko)
NZ (1) NZ228267A (ko)
PT (1) PT90027A (ko)
ZA (1) ZA891524B (ko)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0201165B1 (en) * 1985-03-14 1994-07-20 Beecham Group Plc Medicaments for the treatment of emesis
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
FR2698871B1 (fr) 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
US6190691B1 (en) 1994-04-12 2001-02-20 Adolor Corporation Methods for treating inflammatory conditions
EP0757558A4 (en) * 1994-04-12 1999-06-16 Alza Corp METHOD FOR DETECTING AGENTS THAT MODULATE AN INFLAMMATORY SKIN REACTION
US5962477A (en) * 1994-04-12 1999-10-05 Adolor Corporation Screening methods for cytokine inhibitors
JP3492763B2 (ja) 1994-06-03 2004-02-03 エスエス製薬株式会社 白金錯体及びこれを含有する悪性腫瘍治療剤
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US6573282B1 (en) 1995-09-12 2003-06-03 Adolor Corporation Peripherally active anti-hyperalgesic opiates
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
AUPQ641100A0 (en) * 2000-03-23 2000-04-15 Australia Nuclear Science & Technology Organisation Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents
EA007481B1 (ru) * 2001-09-24 2006-10-27 Тоск, Инк. Цисплатиновые составы пониженной токсичности и способы их применения
EP1523984B1 (de) * 2003-10-13 2006-12-06 Salama, Zoser B. nat.rer.Dr. Pharmazeutische Zusammensetzung umfassend Oxoplatin und dessen Salze
US8956161B2 (en) * 2008-11-04 2015-02-17 Duane C Keller Article and method for controlling oral-originated systemic disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3714159A (en) * 1971-03-30 1973-01-30 Janssen Pharmaceutica Nv 2,2-diaryl-4-(4'-aryl-4'-hydroxy-piper-idino)-butyramides
US4175133A (en) * 1977-02-18 1979-11-20 United States Of America 1,2-Diaminocyclohexane platinum (II) complexes having antineoplastic activity against L1210 leukemia
US4116963A (en) * 1977-05-23 1978-09-26 G.D. Searle & Co. 3,3,3-triarylalkyl-4-phenylalkyl-4-hydroxy piperidines and related compounds
US4194045A (en) * 1977-12-27 1980-03-18 G. D. Searle & Co. 1-(3,3-Diaryl-3-oxadiazolalkyl)-4-phenyl-4-piperidinomethanols and related compounds
CA1158558A (en) * 1980-05-27 1983-12-13 Terence J. Ward Antidiarrhoeal agents
US4536386B1 (en) * 1981-01-26 1995-03-07 Robins Co Inc A H Method of controlling emesis caused by cisplatin in cancer chemotherapy
GB8328218D0 (en) * 1983-10-21 1983-11-23 Johnson Matthey Plc Oral compositions
US4599352A (en) * 1984-03-01 1986-07-08 The United States Of America As Represented By The Department Of Health And Human Services Antineoplastic platinum (IV) complexes and compositions
EP0201165B1 (en) * 1985-03-14 1994-07-20 Beecham Group Plc Medicaments for the treatment of emesis
GB8515845D0 (en) * 1985-06-22 1985-07-24 Beecham Group Plc Treatment
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
US4793986A (en) * 1987-02-25 1988-12-27 Johnson Matthey, Inc. Macromolecular platinum antitumor compounds

Also Published As

Publication number Publication date
PT90027A (pt) 1989-11-10
GB8806224D0 (en) 1988-04-13
NO891122L (no) 1989-09-18
NZ228267A (en) 1990-12-21
IL89502A0 (en) 1989-09-10
AU3112789A (en) 1989-09-21
AU613720B2 (en) 1991-08-08
ZA891524B (en) 1989-10-25
US4892735A (en) 1990-01-09
FI890951A0 (fi) 1989-02-28
DK105889A (da) 1989-09-17
FI890951A (fi) 1989-09-17
JPH0296523A (ja) 1990-04-09
DK105889D0 (da) 1989-03-06
EP0339772A1 (en) 1989-11-02
NO891122D0 (no) 1989-03-15

Similar Documents

Publication Publication Date Title
KR890014107A (ko) 백금 화학 요법약제
KR880008986A (ko) D 계열 프로스타글란딘, 및 그를 함유하는 정신안정제와 최면제
KR910011896A (ko) 신규한 글리코펩티드 유도체
KR870003974A (ko) 비시클로 치환된 페닐아세토니트릴 유도체
KR830009036A (ko) 카르보스티릴 유도체의 제법
KR950031068A (ko) 골다공증의 복합 치료
FR2361901A1 (fr) Derives de substitution de nucleotides et medicament contenant ces substances
KR890016966A (ko) 신규 항바이러스제
BR0110837A (pt) Quimioterapia de combinação
TR200401716T4 (tr) Yeni üç yerdeğiştirme gruplu fenil türevleri ve analogları
KR880007552A (ko) 암민-지환식아민-백금 착화합물 및 항 종양제
BR9811137A (pt) Processo para redução de hiperglicemia e processo para redução de hiperglicemia e estabilização do nìvel de glicose sérica, composição farmacêutica, e, uso de tripicolinato crÈmico sintético
KR920016089A (ko) 제i형 당뇨병의 치료방법
TR200000153T2 (tr) İl-5 inhibite eden 6-azaurasil türevleri.
KR910004557A (ko) 2,4,6-치환 페놀 유도체
KR910005859A (ko) 항종양제
KR890006639A (ko) 벤조티아진 디옥사이드 유도체
KR900007415A (ko) 기억장해 개선약
KR920701220A (ko) 신규의 복핵 백금 착체 및 이를 유효성분으로하는 항종양제
KR920017668A (ko) 암 전이 억제 또는 예방 방법 및 이를 위한 제제
KR920005986A (ko) 혈소판 응집 억제용 약제학적 조성물
KR910005860A (ko) 항간질환성 조성물
KR880004810A (ko) 소화성 궤양 치료제
KR980002033A (ko) 트리아졸 유도체 또는 그 염
KR900701273A (ko) 진토성 에르골린 유도체

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid